Drug Price Fix Seen in Supply of Generics, Rebates, Senator Says
(Bloomberg) -- Streamlining the pharmaceutical supply chain and getting more generic drugs to market would help consumers who can't afford prescriptions, the head of the U.S. Senate's special committee on aging said in a Bloomberg TV interview.
“There are a lot of people getting very wealthy along this supply chain,” while regular Americans are paying “crushingly high” prices for their drugs, Senator Susan Collins, a Republican from Maine, said Wednesday.
The rebates and discounts on drugs from pharmaceutical companies -- which she said set high list prices to begin with -- are offered to middle men without being passed down to consumers, Collins said. Another area that needs change is patent “gaming,” in which brand-name manufacturers file multiple patents on a drug in order to keep competitors out of the market, she added.
“Sometimes the generic drug companies have a hard time getting enough samples of the drug” to run tests needed to meet bio-equivalency requirements from the Food and Drug Administration, Collins said. “Where there are shortages of prescription drugs, we ought to be able to import from a country like Canada that has lower prices,” she added.
The Senate Special Committee on Aging is holding a three-part hearing on prescription drug pricing that started Wednesday and continues Thursday. This week the committee is hearing from people affected by high drug prices and policy experts. Collins said that later this Spring the committee will hear from administration officials on what they're doing to make the cost of drugs more transparent and affordable.
To contact the reporter on this story: Laura Curtis in Washington at lcurtis7@bloomberg.net
To contact the editors responsible for this story: Kasia Klimasinska at kklimasinska@bloomberg.net, John Hughes, Elizabeth Wasserman
©2019 Bloomberg L.P.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
-
Navigating Energy Crossroads: S Jaishankar's Call For Diversified Supply Chains At G20 Ministerial Meeting
As geopolitical fault lines continue to test maritime trade routes and commodity flows, Jaishankar's message remains pertinent: true economic resilience requires open markets, protected transit lines, and a genuine commitment to multilateral cooperation rather than coercion.
-
Indians Are Travelling, But Not Every Journey Is A Holiday | The Week In Whys
Pilgrims, patients and working women are the real travellers, and the system hasn't quite caught up with them.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
